National registry for ovarian and endometrial cancer patients
Official title: SMARAGD - Clinical Research Platform on Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancer Treatment and Outcomes
Run by iOMEDICO AG · NCT05129969 · Data updated 2026-11-12
This study is setting up a national registry to track information about patients with advanced ovarian and endometrial cancer in Germany to see how they respond to different treatments over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 1975 (estimated) |
| Sponsor | iOMEDICO AG Industry-sponsored |
| Locations | 1 site (Multiple Locations) |
| Status | Recruiting |
| Started | November 25, 2021 |
| Main results expected | December 2030 |
| Study ends | December 2030 |
| Registry record updated | January 28, 2026 |
| Trial ID | NCT05129969 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with advanced or metastatic ovarian cancer or endometrial cancer who are starting systemic treatment.
✕Probably not a fit
Patients with early-stage ovarian or endometrial cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to establish a national, prospective, longitudinal tumor registry platform in Germany for patients with advanced or metastatic ovarian and endometrial cancer. It will document uniform data on patient characteristics, molecular diagnostics, treatment regimens, and disease progression while collecting patient-reported outcomes. Patients will be followed for up to three years to identify common therapeutic sequences and changes in treatment. The registry will also include a decentralized biobank to support future research.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of treatment patterns and improve patient outcomes for those with advanced ovarian and endometrial cancers.
How similar studies have gone: Other similar registry studies have shown success in documenting treatment patterns and improving patient care, indicating this approach is promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer): * patients with FIGO stage IIb-IV OC who are starting systemic treatment or * patients with recurrent/relapsed disease, who received any previous systemic anti-tumor treatment and who are now starting systemic treatment for recurrent/relapsed disease. * Locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy. * Signed and dated informed consent (IC): * Patients participating in PRO module: IC before first therapy cycle * Patients not participating in PRO module: IC no later than six weeks after start of first therapy cycle Exclusion Criteria: * newly diagnosed early-stage OC (FIGO stage I-IIa) * Low grade mOC OR * Early-stage EC (FIGO stage I-II)
Where it's running
-
Multiple sites all over Germany
Multiple Locations, Germany Recruiting
Study contacts
- Study coordinator: iOMEDICO AG
- Email: info@iomedico.com
- Phone: +49 761 15242-0
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based precision oncology clinical trial matching and registry
This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.
-
Early diagnosis of ovarian and endometrial cancer using genomic testing
This study is testing a new DNA test to see if it can help catch ovarian and endometrial cancers early by looking for specific changes in samples taken from the cervix and uterus.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy
The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.